PUBLIC COMPANY
saveBoehringer Ingelheim Corp
updated 5mo ago
C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one.
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval222 co-mentions · 111 sources
- drugTRIJARDY XR96 co-mentions · 89 sources
- tagSmall Molecule96 co-mentions · 95 sources
- drugSYNJARDY35 co-mentions · 35 sources
- drugempagliflozin26 co-mentions · 26 sources
- drugJARDIANCE26 co-mentions · 26 sources
- drugCYLTEZO24 co-mentions · 12 sources
- drugHUMIRA24 co-mentions · 12 sources
pipeline
27
marketed
20
phase 3
0
catalysts ytd
3
approvals ytd
3
recalls ytd
0
Pipeline(27)
view full pipeline →pipeline depth27 products
20Marketed7Unknown
Marketed
(empagliflozin + linagliptin + metformin hydrochloride) ER
Type 2 Diabetes
Marketed(empagliflozin + linagliptin)
Type 2 Diabetes
Marketed(empagliflozin + metformin hydrochloride ER)
Type 2 Diabetes
Marketed(linagliptin + metformin hydrochloride) ER
Type 2 Diabetes
Marketed(olodaterol hydrochloride + tiotropium bromide)
Chronic Bronchitis
MarketedCYLTEZO
MarketedCombivent Respimat
Bronchospasm
MarketedLINAGLIPTIN
Type 2 Diabetes
MarketedMicardis HCT
Hypertension
MarketedOfev
Systemic Sclerosis (Scleroderma)
MarketedSYNJARDY
Cardiovascular Risk Factors
MarketedSpiriva
Bronchospasm
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlightThe FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech hist…biospace · 1d ago
- Their loss, our gain? Canada makes its case to Europe amid U.S. instabilityCompanies at BIO-Europe said shifting U.S. politics have created an opening to promote Canada’s strengths to European partners.biospace · 2d ago
- Gubra CEO gets the quick hook; Ex-HHS official Brett Giroir takes over at cancer biotech→ AbbVie and Boehringer Ingelheim’s Danish obesity partner Gubra is going with a co-CEO arrangement after the abrupt departure of Markus Rohrwild. Endpoints News just spoke with Rohrwild last month…endpoints · 6d ago
- Drug price hikes in Germany could push US costs higher, study saysThe report comes amid escalating tensions between the U.S. and Germany over drug prices, with several large pharmaceutical companies responding by scaling back investments in the country.biopharma_dive · 7d ago
- Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked NovemberNovartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about th…biospace · 8d ago
- Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorderHaving linked its glucagon/GLP-1 candidate to a significant reduction in heavy drinking days, Altimmune is preparing to speak to the FDA in December about the design of a Phase 3 program.biospace · 8d ago
- FDA orders class-wide GLP-1 label update to include potential risk for rare eye diseaseTwelve marketed drugs, including Eli Lilly’s and Novo’s weight loss mega-blockbusters, will require a label change under the new FDA update.biospace · 9d ago
- Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage testThe Phase 3 results help clarify the safety profile of Zealand and Boehringer Ingelheim’s survodutide, but analysts do not think the drug will find utility beyond patients with liver-related risk f…biospace · 9d ago
- #AHA26: Boehringer to seek approval of obesity shot, but gaining market share could be trickyBoehringer Ingelheim will seek approval for its incretin shot survodutide for obesity next year, after a trial showed that the drug doesn’t increase patients’ risk of cardiovascular events like hea…endpoints · 9d ago
- Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step downThe deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.biopharma_dive · 13d ago
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that